·The first new-generation recombinant human coagulation factor VIII derived from a humanized cell line ·Benefiting 140,000 haemophilia patients ·The only new-generation recombinant Factor VIII (rFVIII) in China derived from a humanized cell line ·Both the preparation process and formulation are new patents

*For contraindications and adverse reactions, please see the package insert

·The world's first CD20 monoclonal antibody ·Authoritative guidelines such as NCCN and CSCO recommend R-based regimens (treatment regimens based on Rituximab) as the first choice for the treatment of lymphomas such as DLBCL, FL, MZL, MCL, and CLL/SLL ·Strictly follows biosimilar development standards

*For contraindications and adverse reactions, please see the package insert

·The first third-generation immunomodulatory drug to be marketed in China ·Multiple authoritative domestic and international guidelines, including CSCO and NCCN, unanimously recommend Pomalidomide as a cornerstone therapeutic drug for multiple myeloma

*For contraindications and adverse reactions, please see the package insert

·A neurokinin-1 (NK-1) receptor antagonist ·Used for the prevention of acute and delayed nausea and vomiting associated with chemotherapy (especially highly emetogenic chemotherapy) ·Covers highly/moderately emetogenic chemotherapy ·Especially suitable for patients who cannot take oral medication or require rapid onset, significantly improving quality of life and chemotherapy tolerance

*For contraindications and adverse reactions, please see the package insert

·A breakthrough in the treatment of refractory chronic immune thrombocytopenia, filling the gap in second-line treatment ·Covers adult and pediatric patients aged 6 and above

*For contraindications and adverse reactions, please see the package insert

·First generic drug in China ·A second-generation oral tyrosine kinase inhibitor (TKI) ·Approved for pediatric indications ·Listed as a core drug for second-line treatment of chronic myeloid leukemia (CML) in the "CSCO Guidelines for the Diagnosis and Treatment of Malignant Hematological Diseases" and "NCCN Guidelines"

*For contraindications and adverse reactions, please see the package insert

·An oral androgen biosynthesis inhibitor ·Mainly used for the treatment of metastatic castration-resistant prostate cancer (mCRPC) ·The combination regimen with glucocorticoids provides an important treatment option for patients with advanced prostate cancer, especially for disease control and quality of life improvement in the castration-resistant stage

*For contraindications and adverse reactions, please see the package insert

·The only generic lenvatinib drug in China to successfully challenge the patent ·A cornerstone drug for the first-line systemic treatment of hepatic cancer, significantly prolonging median OS and PFS in patients with hepatitis B-related cancer ·Recommended as the first-line gold standard in NCCN guidelines/guidelines for the diagnosis and treatment of primary hepatic cancer/CSCO guidelines, etc.

*For contraindications and adverse reactions, please see the package insert

·First generic drug in China ·Winner of the "Special Award for Generic Drugs" from the China Chemical and Pharmaceutical Industry ·Included in multiple authoritative domestic and international guidelines such as CSCO and CACA

*For contraindications and adverse reactions, please see the package insert